

Press release

Lund 06 October 2022

Scandinavian ChemoTech expands its management team with further clinical competency

We are very pleased to announce the appointment of Dr Mufti as our Medical Director. Dr Mufti has been playing a crucial part as a consulting Medical Advisor where he, amongst other things, has been representing ChemoTech and our technology in the preparations to start the TSE trial at AIIMS Jodhpur.

Dr Mufti is a board-certified onco-pathologist and translational oncology professional with extensive experience in the design and execution of early-phase clinical trials and non-clinical regulatory studies. He did his medical graduated from the prestigious Government Medical College, Srinagar and completed his Pathology residency at the National Board of Examinations and Translational Medicine training at the University of Edinburgh. He brings over 15 years of experience in Oncology research and has extensive experience in Head and Neck, Breast and Soft Tissue tumours.

"It is an honour and the beginning of yet another exciting scientific journey for me to work for Scandinavian ChemoTech which is an ethical and research-oriented oncology therapeutic solutions company. As the Medical Director of ChemoTech, I envision the flagship patented technology called "Tumour Specific Electroporation" (TSE) to achieve its true potential of being included in the earlier and curative lines of treatment for solid tumours. Apart from safe and efficacious electrochemotherapy outcomes, its immune modulation and radiosensitizing potential make me believe that newer treatment paradigms and models can be developed for superficial and deep difficult-to-treat solid cancers. I further envisage TSE foraying into new prospects like Electrochemotherapy via Minimally Invasive Surgical Procedures for deep solid tumours and Electrogenetherapy.

At ChemoTech the Medical Affairs and Clinical Development team will be further strengthened to support the R&D with robust clinical designs, efficient operations, clean data management, real-world data accrual, clinical trial informatics systems and regulatory insights for practical and appropriate use of scientific knowledge from bench to bedside and vice versa." – says Dr Suhail Mufti, Medical Director at Scandinavian ChemoTech

"We are very happy that we now have a Medical Director of this calibre to run the clinical operations of the Company. Dr Suhail Mufti will be ultimately responsible for our clinical studies and also contribute to the training of healthcare personnel and the design of our research and development programs." - says Lars Hedbys, Chairman of the board at Scandinavian ChemoTech

For more information, please contact:
Mohan Frick, CEO

+46 (0)10-218 93 00
ir@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.